Short Bowel Syndrome

The PBS subsidises teduglutide for patients with type III short bowel syndrome with intestinal failure.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with teduglutide under the National Health Act 1953, section 100 for patients with type III short bowel syndrome (SBS) with intestinal failure.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing teduglutide.

Section 100 arrangements

Teduglutide

This item is only PBS-subsidised for day admitted patients, non-admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public participating hospital
  • a public hospital.

You must include the hospital name and provider number on the authority application form. This item isn’t PBS-subsidised for hospital in-patients.

Treatment specifics

To be eligible for PBS-subsidised treatment with teduglutide, patients must be treated by a gastroenterologist or by a specialist within a multidisciplinary intestinal rehabilitation unit.

Applications

Applying for initial treatment

Apply for authority approval to prescribe initial PBS-subsidised teduglutide to treat SBS in writing and either:

All applications must include the completed:

Applying for recommencing treatment

Apply for authority approval to recommence PBS-subsidised teduglutide to treat SBS in writing and either:

All applications must include the completed:

First continuing treatment

Apply for authority approval for first continuing PBS-subsidised teduglutide treatment of SBS in writing and either:

All applications must include the completed:

Subsequent continuing treatment

Apply for authority approval for subsequent continuing PBS-subsidised teduglutide for treatment of SBS in writing and either:

All applications must include the completed:

Further information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 26 September 2022.
QC 51483